SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Tesla, Inc. engages in the design, development, manufacture, and sale of electric vehicles and energy generation and storage systems. It operates through the Automotive and Energy Generation and Storage segments. The Automotive segment includes the design, development, manufacture, sale, and lease of electric vehicles as well as sales of automotive regulatory credits. The Energy Generation and Storage segment is involved in the design, manufacture, installation, sale, and lease of solar energy generation, energy storage products, and related services and sales of solar energy systems incentives. The company was founded by Jeffrey B. Straubel, Elon Reeve Musk, Martin Eberhard, and Marc Tarpenning on July 1, 2003 and is headquartered in Austin, TX.

Tesla Inc

Tesla is currently facing significant selling pressure amid broader market volatility, with the community actively debating whether the stock is a long-term value opportunity or a sinking asset due to execution risks and high valuation concerns. Investors are closely monitoring the stock's technical support levels as bearish sentiment surges over delivery performance and potential capital rotation into other ventures.

SPDR S&P 500 ETF TRUST - Units of undivided interest in SPDR Trust Series 1

The SPY is experiencing significant volatility and fragmented sentiment as market participants brace for an upcoming press conference regarding geopolitical tensions and the conflict with Iran. The community is actively debating the reliability of ceasefire rumors while monitoring price action for signs of an institutional 'rug pull' or potential market-moving headlines.

Invesco QQQ Trust Series 1 - Units of beneficial interest

Invesco QQQ Trust is experiencing heavy volatility as investors weigh conflicting reports of ceasefire negotiations against ongoing military tensions in the Middle East, leading to intense debate among market participants about whether current price action reflects genuine growth or orchestrated market manipulation. The community is actively parsing news regarding geopolitical deadlines and oil price shifts while attempting to navigate algorithmic swings driven by uncertainty.

Trump Media & Technology Group Corp. engages in operating social media and in the technology business. Its brands include TRUTH Social, TMTG+, and TMTG News. It operates through the Media and Truth.Fi segments. The Media segment includes products and services such as advertisement through the Truth Social platform. The Truth.Fi segment relates to customized exchange-traded funds or exchange-traded products invested in America First principles, and bitcoin and similar cryptocurrencies or crypto-related securities. The company was founded on March 28, 2024 and is headquartered in Sarasota, FL.

Trump Media & Technology Group Corp.

DJT is trending as the community debates the geopolitical volatility surrounding the escalating conflict with Iran, highlighted by threats to regional energy infrastructure and ongoing tensions over the Strait of Hormuz. Investors and political commentators remain sharply divided, with discussions centered on the potential market impact of these developments, skepticism toward official press briefings, and the broader implications for the U.S. domestic economy and national security.

Mega Fortune Co., Ltd. operates as a holding company which provides information technology services. It specializes in delivering comprehensive IoT solutions and services across various industries. The firm offers low carbon property management, energy, stock and GreenTech management services. The company was founded in 2011 and is headquartered in Hong Kong.

Mega Fortune Co Ltd.

Mega Fortune Company Limited

Mega Fortune Company Limited ($MGRT) is trending as retail traders monitor its volatile price action and frequent trading halts, often comparing its movement to other low-float Chinese IPOs. The community remains deeply divided, with some betting on a potential squeeze and parabolic gains, while many others warn of a typical 'pump and dump' scam that frequently characterizes similar recent market entrants.

Aehr Test Systems engages in the design, manufacture, market, and sale of test and burn-in equipment used in the semiconductor industry. Its products include FOX-XP, FOX-NP, and FOX-CP wafer contact parallel test and burn-in systems, the WaferPak full wafer contactor, the DiePak Carrier, the WaferPak Aligner, the DiePak Autoloader, and test fixtures. The company was founded by Rhea J. Posedel on May 25, 1977 and is headquartered in Fremont, CA.

Aehr Test Systems

Aehr Test Systems is surging as investors cheer the company's strategic pivot into AI infrastructure and recent high-profile production orders for its ultra-high-power testing systems. The community is heavily focused on the company's role as a critical bottleneck gatekeeper for reliability in the hyperscale data center supply chain, fueling bullish sentiment around upcoming earnings and guidance.

United States Oil Fund LP - United States Oil Fund

United States Oil Fund

The United States Oil Fund is trading amidst intense market volatility as investors weigh the impact of an escalating geopolitical conflict in the Strait of Hormuz against ongoing, often contradictory, ceasefire reports. Community discourse is heavily polarized, with many market participants expressing frustration over potential market manipulation and the unpredictable nature of administration rhetoric regarding war timelines.

Enovix Corp. engages in the design and development of silicon-anode lithium-ion batteries. The firm's proprietary 3D cell architecture increases energy density and maintains a high cycle life. It is also developing its 3D cell technology and production process for the electric vehicle and energy storage markets to help enable utilization of renewable energy. The company was founded by Mr. Harrold Jones Rust, III, Ashok Lahiri, and Murali Ramasubramanian in November 2006 and is headquartered in Fremont, CA.

Enovix Corporation

Enovix Corp

Enovix is currently experiencing significant downward pressure, with shares recently hitting fresh all-time lows amid ongoing frustration regarding manufacturing scale-up delays and missed quarterly milestones. While the community remains polarized, with some bulls pointing to a significant cash position and potential upside from future customer purchase orders, many traders are vocal about the lack of consistent execution and are actively discussing the possibility of further price declines toward the mid-four-dollar range.

AXT, Inc. engages in the design, development, manufacture and distribution of compound and single element semiconductor substrates. It also sells specialty material substrates and raw materials used to make substrates and other related products. The company was founded by Morris S. Young and Davis Zhang in 1986 and is headquartered in Fremont, CA.

AXT Inc

AXT Inc. is seeing intense volatility and aggressive trading as investors debate whether recent price action is a fundamental valuation correction driven by AI-related substrate demand or a speculative bubble prone to a sharp reversal. The community remains deeply divided, with many traders monitoring for a potential dilution event while others emphasize the company's critical role in the photonics supply chain.

“Buttcoin - The Next Bitcoin” is the memecoin version of Bitcoin. Launched on January 30, 2025, on Pump.fun, it’s a community-owned memecoin on Solana. The idea was inspired by a 4:20 minutes long YouTube video from 2013 called "The Next Bitcoin?" by James D. McMurray.

Buttcoin

Buttcoin is gaining significant community attention as a long-standing memecoin project that proponents are positioning as a humorous, culturally driven alternative to Bitcoin. Investors are actively discussing its historical roots, speculative long-term potential, and its role as a narrative-heavy asset within the broader meme-driven crypto sector.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Top Pharmaceutical Stocks To Add to Your Watchlist - November 6th

Eli Lilly and Company, Pfizer, Novo Nordisk A/S, 89BIO, McKesson, AbbVie, and Teva Pharmaceutical Industries are the seven Pharmaceutical stocks to watch today, according to MarketBeat's stock...

RHHBY's Sales Up 7% in First 9 Months of 2025, '25 Earnings View Raised 

Roche's Q3 sales climbed 6% to CHF 14.9B, powered by surging demand for Phesgo, Xolair, Hemlibra, Vabysmo, and Ocrevus.

SHAREHOLDER RIGHTS ALERT: Halper Sadeh LLC Investigates SWKH, ETNB, BRNS, VRNT on Behalf of Shareholders

SHAREHOLDER RIGHTS ALERT: Halper Sadeh LLC Investigates SWKH, ETNB, BRNS, VRNT on Behalf of Shareholders SHAREHOLDER RIGHTS ALERT: Halper Sadeh LLC Investigates SWKH, ETNB, BRNS, VRNT on Behalf of...

Roche Wins FDA Nod for Label Expansion of Tecentriq in Lung Cancer

Roche gains FDA approval for Tecentriqs expanded label, marking the first combo maintenance therapy for extensive-stage small cell lung cancer. 

Shares of Viking Therapeutics rose 3.4% to $26.25 on Monday and extended gains after hours,&nbsp;with a Wall Street research firm suggesting the biopharma is benefiting from Pfizer’s buyout offer for Metsera as it looks to bolster its obesity drug pipeline.BTIG reiterated a ‘Buy’ rating and $125 price target on&nbsp;Viking’s stock, saying the transaction sharpens&nbsp;the company’s&nbsp;clinical updates and strategic optionality while bolstering sentiment ahead of key readouts. The commentary followed&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/89bio-stock-surges-roche-3-5b-buyout-wall-street-analyst-cautious/chDdNVaR3br">Roche’s acquisition of 89bio</a>, signaling increased deal activity in the biotech space.Meanwhile,&nbsp;<a href="https://stocktwits.com/symbol/MTSR">Metsera’s stock</a> surged to an all-time high Monday, marking their biggest one-day gain ever.&nbsp;As part of the deal, Pfizer will pay Metsera $47.50 in cash per share, giving the company an enterprise value of $4.9 billion. If three clinical milestones are achieved, additional payments of $22.50 per Metsera share will be made, bringing the total value of the deal to as much as $7.3 billion. The deal is expected to close in the fourth quarter of 2025, pending approvals.Metsera, a clinical-stage biotech developing therapies for obesity and cardiometabolic diseases, will add four differentiated programs to Pfizer's pipeline. The assets include weekly and monthly injectable GLP-1 receptor agonists, two orally delivered GLP-1 candidates, and MET-233i, a monthly injectable amylin analog. The company previously discontinued its own obesity candidate Danuglipron.Viking was also in the spotlight, with Daniel Newman, CEO of Futurum Equities,&nbsp;<a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://x.com/danielnewmanUV/status/1970178447411683535">posting on X</a> that Viking’s valuation “just got a massive shot in the arm with the Pfizer deal to buy Metsera,” describing Metsera’s GLP-1 program as “a far less exciting GLP” and arguing that Viking is “worth far more than $7.2 billion.”On Stocktwits, retail sentiment was ‘extremely bullish’ for both Pfizer and Metsera amid ‘extremely high’ message volume, while Viking drew ‘bullish’ sentiment alongside ‘high’ activity.One bullish user said Viking management had likely rejected lowball offers from large pharma, leaving rivals to acquire ‘inferior pipelines.<stembedurl>https://stocktwits.com/deerhtide/message/629602680</stembedurl>Another pointed to debate over whether Viking should pursue a buyout or go-it-alone strategy, adding that CEO Brian Lian’s stake of more than two million shares aligns him with investors. The user disclosed holding 83,000 shares, calling the position conviction-driven.<stembedurl>https://stocktwits.com/SauceMan912/message/629604221</stembedurl>So far this year,&nbsp;<a href="https://stocktwits.com/symbol/PFE">Pfizer’s stock</a> is down 4.5%, Metsera’s shares have more than doubled, and&nbsp;<a href="https://stocktwits.com/symbol/VKTX">Viking Therapeutics’ stock</a> has fallen 34.8%.For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, a person holds a smartphone displaying the logo of Viking Therapeutics on July 19, 2025. (Photo illustration by Cheng Xin/Getty Images)

Viking Therapeutics Stock Gets Boost From Pfizer-Metsera Deal, Says BTIG — Retail Slams Rivals For Buying ‘Inferior Pipelines’

BTIG said Pfizer’s $7.3 billion Metsera acquisition sharpens its clinical updates and strategic optionality.

Equity

Wolfe Research’s Andy Chen cut his rating on 89bio to 'Peer Perform' from 'Outperform'&nbsp;and did not assign a price target after the biotech firm agreed to a $3.5 billion takeover by Roche.&nbsp;<a href="https://stocktwits.com/symbol/ETNB">89bio’s stock</a> surged 85% on Thursday to end at $14.96, its best day on record and the highest level in about a year and a half, before easing 0.03% in after-hours trading.<a href="https://stocktwits.com/news-articles/equity/markets/why-did-89bio-stock-nearly-double-in-value/chDcHJIR3bc">Roche is paying $14.50 a share in cash for 89bio</a>, about 79% above where the stock closed on Wednesday. Investors will also get the chance at another $6 a share in cash if certain milestones are met, though those rights won’t be tradable.&nbsp;On a fully diluted basis, the transaction values 89bio at up to $3.5 billion. An affiliate of Roche will launch a tender offer to acquire all outstanding shares, with closing expected in the fourth quarter, subject to customary conditions. Until then, 89bio will continue to operate independently before joining Roche’s pharmaceuticals division.The acquisition brings Roche 89bio’s late-stage drug candidate Pegozafermin, which is being developed for the treatment of metabolic dysfunction-associated steatohepatitis (MASH) with advanced fibrosis. MASH is a progressive liver disease characterized by fat accumulation leading to inflammation and tissue damage.According to Koyfin, 89bio’s stock has an average 12-month analyst price target of $30.8, with estimates ranging from $12 to $55. The company is covered by 10 analysts, with seven ‘Buy’ ratings, two ‘Hold,’ and no ‘Sell.’ The average rating is ‘Buy.’&nbsp;On Stocktwits, retail sentiment around 89bio was described as 'extremely bullish' with 'extremely high' message volume, while sentiment on Roche was 'bullish' with 'normal' activity.One user noted that Roche’s purchase of 89bio could be part of a broader strategic shopping spree, adding that Sarepta Therapeutics might be next, given the two companies’ long-standing partnership. The user also suggested that Amgen or Pfizer could make competing offers and stated that they planned to hold their position and watch developments.<stembedurl>https://stocktwits.com/GaborPiscis/message/629152949</stembedurl>Another user wondered whether Tempest Therapeutics might be a possible target for Roche following the 89bio deal.<stembedurl>https://stocktwits.com/Fandango23/message/629193287</stembedurl>While 89bio’s stock has risen 91% so far in 2025,&nbsp;<a href="https://stocktwits.com/symbol/RHHBY">Roche’s stock</a> has climbed 21% over the same period.For updates and corrections, email newsroom[at]stocktwits[dot]com.

While 89bio’s stock (ETNB) has risen 91% so far in 2025, Roche’s stock (RHHBY) has climbed 21% over the same period. (Photo credit: Getty Images)

89bio Stock Skyrockets After Roche’s $3.5B Buyout Offer: Retail Bullish, But A Wall Street Analyst Is Cautious 

The acquisition brings Roche rights to Pegozafermin, now in late-stage trials for liver disease MASH.

RHHBY to Acquire 89bio for $3.5B, Add Late-Stage MASH Drug to Pipeline 

Roche is set to acquire 89bio for $3.5B, adding late-stage MASH drug pegozafermin to its cardiovascular, renal, and metabolic pipeline. 

Shares of 89bio, Inc. (ETNB) jumped 86% in the pre-market session on Thursday after the company said that it has entered into a merger agreement to be acquired by Roche (RHHBY) for up to $3.5 billion on a fully diluted basis.The company <a target="_blank" rel="noopener noreferrer nofollow" href="https://ir.89bio.com/news-releases/news-release-details/89bio-inc-announces-agreement-be-acquired-roche">stated</a> that Roche will acquire it for $14.50 per share in cash at closing, representing a premium of approximately 79% to the stock’s closing price on Wednesday. 89bio shareholders will also receive a non-tradeable contingent value right to receive up to an aggregate of $6 per share in cash receivable upon the achievement of certain milestones.On Stocktwits, retail sentiment around <a href="https://stocktwits.com/symbol/ETNB">ETNB stock</a> jumped from ‘neutral’ to ‘extremely bullish’ territory over the past 24 hours, while message volume rose from ‘normal’ to ‘extremely high’ levels.<figure class="image"><img style="aspect-ratio:573/59;" src="https://news.stocktwits-cdn.com/Screenshot_2025_09_18_at_7_35_04_AM_png_e0cb1a5888.webp" alt="ETNB's Sentiment Meter and Message Volume as of 7:35 a.m. ET on Sept. 18, 2025 | Source: Stocktwits" width="573" height="59"><figcaption>ETNB's Sentiment Meter and Message Volume as of 7:35 a.m. ET on Sept. 18, 2025 | Source: Stocktwits</figcaption></figure> A Stocktwits user urged investors to buy the stock now.<stembedurl>https://stocktwits.com/FlyingChemist01/message/629085636</stembedurl>Another opined that the buyout represents a broader trend in which good biopharmaceutical firms are being acquired.<stembedurl>https://stocktwits.com/John62/message/629085287</stembedurl>Under the deal, an affiliate of Roche will commence a tender offer to acquire all of 89bio’s outstanding shares.The closing of the transaction is expected to occur in the fourth quarter, subject to the fulfillment of all closing conditions. Until then, 89bio will operate as a separate and independent company. After the closing of the deal, 89bio will join the Roche group as part of its pharmaceuticals division.The deal includes 89bio’s Pegozafermin, currently in late-stage trials for the treatment of metabolic dysfunction-associated steatohepatitis (MASH) with advanced fibrosis. MASH is a progressive disease characterized by the accumulation of fat in the liver, leading to inflammation and tissue damage.ETNB stock is up 3% this year but down approximately 3% over the past 12 months.&nbsp;Read also:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/dow-futures-surge-after-fed-signals-more-rate-cuts-in-2025/chDcuaaR3GC">Dow Futures Surge After Fed Signals Possibility Of More Rate Cuts This Year: META, PLTR, PYPL, GOOGL Among Stocks To Watch</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Rising stock market chart on a trading board background.

Why Did 89bio Stock Nearly Double In Value Today?

89bio announced that Roche will acquire it for $14.50 per share in cash at closing, representing a premium of approximately 79% to the stock’s closing price on Wednesday.

Citi says SMid biotechs alternative to large caps as it starts coverage

Investing.com -- Citi has expanded its biopharmaceutical research coverage, initiating coverage on seven small- and mid-cap (SMid) biotechnology companies. Citi said SMid biotechs remain an attractive alternative to large-cap pharmaceutical firms, particularly amid healthcare policy uncertainties. Citi initiated coverage with Buy ratings on 89bio (NASDAQ:ETNB), price target $25. Apogee (NASDAQ:APOG), price target $95. Avidity, price target $70, BioNTech (NASDAQ:BNTX), price target $145. Kiniksa, price target $40. Kymera, price target $52

Companies developing therapies for metabolic steatohepatitis (MASH) saw strong gains even as Novo Nordisk (<a class="mention" data-mention="$NVO" data-symbol-id="NVO" href="https://stocktwits.com/symbol/NVO" target="_blank">$NVO</a>) announced that its GLP-1 drug, semaglutide, demonstrated “superior improvement” in treating the liver disease in its phase 3 ESSENCE trial.&nbsp;Shares of Madrigal Pharmaceuticals (<a class="mention" data-mention="$MDGL" data-symbol-id="MDGL" href="https://stocktwits.com/symbol/MDGL" target="_blank">$MDGL</a>), which received FDA approval earlier this year for its MASH drug, Rezdiffra, rose by 18% following the announcement, with 89Bio (<a class="mention" data-mention="$ETNB" data-symbol-id="ETNB" href="https://stocktwits.com/symbol/ETNB" target="_blank">$ETNB</a>) and Akero Therapeutics (<a class="mention" data-mention="$AKRO" data-symbol-id="AKRO" href="https://stocktwits.com/symbol/AKRO" target="_blank">$AKRO</a>) seeing gains of 15% and 4%, respectively.Novo Nordisk’s ESSENCE trial, a 240-week, double-blind study involving 1,200 adults with MASH and moderate to advanced liver fibrosis, achieved its primary endpoints.&nbsp;After 72 weeks, patients receiving a weekly dose of 2.4 mg semaglutide showed significant liver fibrosis improvement without worsening steatohepatitis, as well as steatohepatitis resolution with no worsening of liver fibrosis, compared to those on placebo.&nbsp;"We are very pleased about the ESSENCE clinical trial results and the potential of semaglutide to help people living with MASH. Among people with overweight or obesity, one in three live with MASH. This has a serious impact on their health and represents a significant unmet need," said Martin Holst Lange, Novo’s executive vice president.The FDA has yet to approve GLP-1 drugs for MASH, though several early trials have shown promise in reversing the disease’s initial stages.&nbsp;In March, Madrigal’s Rezdiffra became the first FDA-approved treatment for MASH with moderate to advanced liver scarring.&nbsp;On Thursday, Madrigal reported robust quarterly earnings, driven by Rezdiffra sales, which led to raised price targets and positive analyst notes.&nbsp;Canaccord boosted its target on Madrigal to $394, citing confidence in continued revenue growth, while UBS increased its target to $441, highlighting an “underappreciated opportunity” in MASH and potential validation from Novo’s findings.<figure class="image"><a href="https://stocktwits.com/symbol/MDGL"><img style="aspect-ratio:1314/320;" src="https://st-everywhere-cms-prod.s3.us-east-1.amazonaws.com/MDGL_sentiment_and_message_volume_Nov_1_69ab9366a3.png" alt="MDGL sentiment and message volume Nov 1.png" width="1314" height="320"></a><figcaption>MDGL sentiment and message volume Nov 1 as of 1:30 pm ET | source: Stocktwits</figcaption></figure>On Stocktwits, retail sentiment for MDGL remained ‘extremely bullish’ as of Friday afternoon amid a spike in message volume, with many fixated on Thursday’s strong results.<stembedurl>https://stocktwits.com/GXD_Texas/message/590911195</stembedurl>Some were also penciling in the next resistance levels for the stock that broke out over $300 this week.<stembedurl>https://stocktwits.com/TheProphetOfProfit/message/590910821</stembedurl>Madrigal’s stock has surged over 33% year-to-date, significantly outperforming broader market benchmarks.For updates and corrections, email&nbsp;<a target="_blank" rel="noopener noreferrer nofollow" href="mailto:newsroom@stocktwits.com">newsroom@stocktwits.com</a>Read next: <a href="https://stocktwits.com/news-articles/markets/equity/epix-stock-falls-after-drug-trial-fails/cJEYt4ERBm">Essa Pharma Stock Crashes After Lead Drug Candidate Trial Flops: Retail Hopes Fade</a>

On Thursday, Madrigal reported robust quarterly earnings, driven by Rezdiffra sales, which led to raised price targets and positive analyst notes.

Madrigal Pharma Stock Soars Despite Novo Nordisk’s ‘Superior’ MASH Trial Results: Retail Bullish On Earnings Beat

In March, Madrigal’s Rezdiffra became the first FDA-approved treatment for MASH with moderate to advanced liver scarring.

89bio, Inc. is a clinical-stage biopharmaceutical company, which engages in the development and commercialization of innovative therapies for the treatment of liver and cardio-metabolic diseases. Its product pipeline includes pegozafermin, FGF21, NASH, and SHTG. The company was founded on January 18, 2018 and is headquartered in San Francisco, CA.

ETNB
89bio Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Poll

Latest ETNB News

ETNB89bio Inc